{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:01:30Z","timestamp":1777410090257,"version":"3.51.4"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","award":["01EO0901"],"award-info":[{"award-number":["01EO0901"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2018,12,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Cerebellar ataxia is a frequent and often disabling syndrome severely impairing motor\nfunctioning and quality of life. Patients suffer from reduced mobility, and restricted autonomy, experiencing\nan even lower quality of life than, e.g., stroke survivors. Aminopyridines have been\ndemonstrated viable for the symptomatic treatment of certain forms of cerebellar ataxia. This article\nwill give an outline of the present pharmacotherapy of different cerebellar disorders. As a current\nkey-therapy for the treatment of downbeat nystagmus 4-aminopyridine (4-AP) is suggested for the\ntreatment of downbeat nystagmus (5\u201310 mg Twice a day [TID]), a frequent type of persisting nystagmus,\ndue to a compromise of the vestibulo-cerebellum. Studies with animals have demonstrated,\nthat a nonselective blockage of voltage-gated potassium channels (mainly Kv1.5) increases Purkinje-\ncell (PC) excitability. In episodic ataxia type 2 (EA2), which is frequently caused by mutations\nof the PQ-calcium channel, the efficacy of 4-AP (5\u201310 mg TID) has been shown in a randomized\ncontrolled trial (RCT). 4-AP was well tolerated in the recommended dosages. 4-AP was also effective\nin elevating symptoms in cerebellar gait ataxia of different etiologies (2 case series).<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title\/>\n<jats:p>A new treatment option for cerebellar disease is the amino-acid acetyl-DL-leucine, which has significantly\nimproved cerebellar symptoms in three case series. There are on-going randomized controlled\ntrials for cerebellar ataxia (acetyl-DL-leucine vs placebo; ALCAT), cerebellar gait disorders\n(SR-form of 4-AP vs placebo; FACEG) and EA2 (sustained-release\/SR-form of 4-AP vs acetazolamide\nvs placebo; EAT2TREAT), which will provide new insights into the pharmacological treatment\nof cerebellar disorders.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570159x16666180905093535","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:45:47Z","timestamp":1536626747000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders"],"prefix":"10.2174","volume":"17","author":[{"given":"Roger","family":"Kalla","sequence":"first","affiliation":[{"name":"Department of Neurology, German Center for Vertigo and Balance Disorders, and Institute for Clinical Neurosciences, University Hospital Munich, Campus Grosshadern, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[{"name":"Department of Neurology, German Center for Vertigo and Balance Disorders, and Institute for Clinical Neurosciences, University Hospital Munich, Campus Grosshadern, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","volume":"77","author":"Jacobi H.","year":"2011","unstructured":"Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, D\u00fcrr A, Marelli C, Globas C, Linnemann C, Sch\u00f6ls L, Rakowicz M, Rola R, Zdzienicka E, Schmitz-H\u00fcbsch T, Fancellu R, Mariotti C, Tomasello C, Baliko L, Melegh B, Filla A, Rinaldi C, van de Warrenburg BP, Verstappen CC, Szymanski S, Berciano J, Infante J, Timmann D, Boesch S, Hering S, Depondt C, Pandolfo M, Kang JS, Ratzka S, Schulz J, Tezenas du Montcel S, Klockgether T. Neurology, In: Adam, M.P.; Ardinger, H.H.; Pagon, R.A.; Wallace, S.E.; Bean, L.J.H.; Stephens, K.; Amemiya, A. Eds. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1998, 28, 1993-2018. [updated 2018 Sep ]. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.,, 2011, 77,, 1035-1041,[http:\/\/dx.doi.org\/10.1212\/WNL.0b013 e31822e7ca0]. [PMID: 21832].","journal-title":"Neurology"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12311-008-0028-x","volume":"7","author":"Tsuji S.","year":"2008","unstructured":"Tsuji S, Onodera O, Goto J, Nishizawa M. Cerebellum, Sporadic ataxias in Japan--a population-based epidemiological study.,, 2008, 7,, 189-197,[http:\/\/dx.doi.org\/10.1007\/s12311-008-0028-x]. [PMID: 184186].","journal-title":"Cerebellum"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awp056","volume":"132","author":"Erichsen A.K.","year":"2009","unstructured":"Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Brain, Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study.,, 2009, 132,, 1577-1588,[http:\/\/dx.doi.org\/10.1093\/brain\/awp0]. [PMID: 19339].","journal-title":"Brain"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/jnnp.2003.014662","volume":"75","author":"Muzaimi M.B.","year":"2004","unstructured":"Muzaimi MB, Thomas J, Palmer-Smith S, Rosser L, Harper PS, Wiles CM, Ravine D, Robertson NP. J Neurol Neurosurg Psychiatry, Population based study of late onset cerebellar ataxia in south east Wales.,, 2004, 75,, 1129-1134,[http:\/\/dx.doi. org\/10.1136\/jnnp.2003.0146]. [PMID: 15258].","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=5","author":"L\u00f3pez-Bastida J.","year":"","unstructured":"L\u00f3pez-Bastida J, Perestelo-P\u00e9rez L, Mont\u00f3n-Alvarez F. , , ,"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/01.nrl.0000141651.35193.67","volume":"10","author":"Perlman S.L.","year":"2004","unstructured":"Perlman SL. Neurologist, Symptomatic and disease-modifying therapy for the progressive ataxias.,, 2004, 10,, 275-289,[http:\/\/dx. doi.org\/10.1097\/01.nrl.0000141651.35193.]. [PMID: 15335].","journal-title":"Neurologist"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.22740","volume":"25","author":"Schmitz-H\u00fcbsch T.","year":"2010","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, Mariotti C, Filla A, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BP, D\u00fcrr A, Timmann D, Boesch S, Rola R, Depondt C, Sch\u00f6ls L, Zdzienicka E, Kang JS, Ratzka S, Kremer B, Schulz JB, Klopstock T, Melegh B, du Montcel ST, Klockgether T. Mov Disord, Self-rated health status in spinocerebellar ataxia-results from a European multicenter study.,, 2010, 25,, 587-595,[http:\/\/ dx.doi.org\/10.1002\/mds.227]. [PMID: 20175].","journal-title":"Mov Disord"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"Ilg W.","year":"2014","unstructured":"Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claa\u00dfen J, Feil K, Kalla R, Miyai I, Nachbauer W, Sch\u00f6ls L, Strupp M, Synofzik M, Teufel J, Timmann D. Cerebellum, Consensus paper: management of degenerative cerebellar disorders.,, 2014, 13,, 248-268,[http:\/\/dx.doi.org\/10.1007\/s12311-013-0531-]. [PMID: 242226].","journal-title":"Cerebellum"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/jnnp-2012-304736","volume":"84","author":"Claassen J.","year":"2013","unstructured":"Claassen J, Spiegel R, Kalla R, Faldon M, Kennard C, Danchaivijitr C, Bardins S, Rettinger N, Schneider E, Brandt T, Jahn K, Teufel J, Strupp M, Bronstein A. J Neurol Neurosurg Psychiatry, A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms.,, 2013, 84,, 1392-1399,[http:\/\/dx.doi.org\/10.1136\/jnnp-2012-3047]. [PMID: 238137].","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00415-011-5999-8","volume":"258","author":"Strupp M.","year":"2011","unstructured":"Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ. J Neurol, Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.,, 2011, 258,, 1207-1222,[http:\/\/dx.doi.org\/10.1007\/s00415-011-5999-]. [PMID: 214616].","journal-title":"J Neurol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.wco.0000196156.00481.e1","volume":"19","author":"Strupp M.","year":"2006","unstructured":"Strupp M, Brandt T. Curr Opin Neurol, Pharmacological advances in the treatment of neuro-otological and eye movement disorders.,, 2006, 19,, 33-40,[http:\/\/dx.doi.org\/10.1097\/01.wco. 0000196156.00481.e]. [PMID: 164156].","journal-title":"Curr Opin Neurol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s00415-015-7987-x","volume":"263","author":"Kalla R.","year":"2016","unstructured":"Kalla R, Teufel J, Feil K, Muth C, Strupp M. J Neurol, Update on the pharmacotherapy of cerebellar and central vestibular disorders.,, 2016, 263,, S24-S29,[http:\/\/dx.doi.org\/10.1007\/ s00415-015-7987-x]. [PMID: 270838].","journal-title":"J Neurol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/practneurol-2011-000181","volume":"12","author":"Mehta A.R.","year":"2012","unstructured":"Mehta AR, Kennard C. Pract Neurol, The pharmacological treatment of acquired nystagmus.,, 2012, 12,, 147-153,[http:\/\/dx. doi.org\/10.1136\/practneurol-2011-000]. [PMID: 22661].","journal-title":"Pract Neurol"},{"key":"ref=14","author":"Hille B.","unstructured":"Hille B, , ,, , , Channels of Excitable Membranes  3rd Ed; Sinauer: Sunderlang, 2001,-","journal-title":"Channels of Excitable Membranes  3rd Ed; Sinauer: Sunderlang"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s002210100788","volume":"139","author":"Etzion Y.","year":"2001","unstructured":"Etzion Y, Grossman Y. Exp Brain Res, Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells.,, 2001, 139,, 419-425,[http:\/\/dx.doi.org\/10.1007\/s0022101007]. [PMID: 115348].","journal-title":"Exp Brain Res"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2007.04.031","volume":"1156","author":"Yazdi H.H.","year":"2007","unstructured":"Yazdi HH, Janahmadi M, Behzadi G. Brain Res, The role of small-conductance Ca2+-activated K+ channels in the modulation of 4-aminopyridine-induced burst firing in rat cerebellar Purkinje cells.,, 2007, 1156,, 59-66,[http:\/\/dx.doi.org\/10.1016\/ j.brainres.2007.04.0]. [PMID: 174935].","journal-title":"Brain Res"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.03.030","volume":"1212","author":"Haghdoost-Yazdi H.","year":"2008","unstructured":"Haghdoost-Yazdi H, Janahmadi M, Behzadi G. Brain Res, Iberiotoxin-sensitive large conductance Ca2+-dependent K+ (BK) channels regulate the spike configuration in the burst firing of cerebellar Purkinje neurons.,, 2008, 1212,, 1-8,[http:\/\/dx.doi.org\/ 10.1016\/j.brainres.2008.03.0]. [PMID: 184399].","journal-title":"Brain Res"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1007\/s00415-013-7046-4","volume":"260","author":"Shaikh A.G.","year":"2013","unstructured":"Shaikh AG, Marti S, Tarnutzer AA, Palla A, Crawford TO, Zee DS, Straumann D. J Neurol, Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia.,, 2013, 260,, 2728-2735,[http:\/\/dx.doi.org\/10.1007\/s00415-013-7046-]. [PMID: 238847].","journal-title":"J Neurol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270003251388","volume":"43","author":"Hayes K.C.","year":"2003","unstructured":"Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, Blight AR. J Clin Pharmacol, Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.,, 2003, 43,, 379-385,[http:\/\/dx.doi.org\/10.1177\/0091270003251]. [PMID: 12723].","journal-title":"J Clin Pharmacol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1523\/JNEUROSCI.3582-09.2010","volume":"30","author":"Alvi\u00f1a K.","year":"2010","unstructured":"Alvi\u00f1a K, Khodakhah K. J Neurosci, The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.,, 2010, 30,, 7258-7268,[http:\/\/dx.doi.org\/10.1523\/JNEUROSCI.3582-09.20]. [PMID: 205050].","journal-title":"J Neurosci"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1523\/JNEUROSCI.0098-05.2005","volume":"25","author":"Weisz C.J.","year":"2005","unstructured":"Weisz CJ, Raike RS, Soria-Jasso LE, Hess EJ. J Neurosci, Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering.,, 2005, 25,, 4141-4145,[http:\/\/ dx.doi.org\/10.1523\/JNEUROSCI.0098-05.200]. [PMID: 158436].","journal-title":"J Neurosci"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/jnnp.2007.126284","volume":"79","author":"Wagner J.N.","year":"2008","unstructured":"Wagner JN, Glaser M, Brandt T, Strupp M. J Neurol Neurosurg Psychiatry, Downbeat nystagmus: aetiology and comorbidity in 117 patients.,, 2008, 79,, 672-677,[http:\/\/dx.doi.org\/ 10.1136\/jnnp.2007.126]. [PMID: 178729].","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1212\/01.wnl.0000194242.28018.d9","volume":"66","author":"Kalla R.","year":"2006","unstructured":"Kalla R, Deutschlander A, H\u00fcfner K, Stephan T, Jahn K, Glasauer S, Brandt T, Strupp M. Neurology, Detection of floccular hypometabolism in downbeat nystagmus by fMRI.,, 2006, 66,, 281-283,[http:\/\/dx.doi.org\/10.1212\/01.wnl.0000194242.28018.d]. [PMID: 164346].","journal-title":"Neurology"},{"key":"ref=24","author":"Leigh R.J.","year":"2006","unstructured":"Leigh RJ, Zee D. , The neurology of eye movements 4th Ed; Oxford University Press: Oxford, New York, , 2006"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/brain\/awh532","volume":"128","author":"Pierrot-Deseilligny C.","year":"2005","unstructured":"Pierrot-Deseilligny C, Milea D. Brain, Vertical nystagmus: clinical facts and hypotheses.,, 2005, 128,, 1237-1246,[http:\/\/ dx.doi.org\/10.1093\/brain\/awh5]. [PMID: 158720].","journal-title":"Brain"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1152\/jn.2000.83.3.1125","volume":"83","author":"Straumann D.","year":"2000","unstructured":"Straumann D, Zee DS, Solomon D. J Neurophysiol, Three-dimensional kinematics of ocular drift in humans with cerebellar atrophy.,, 2000, 83,, 1125-1140,[http:\/\/dx.doi.org\/10.1152\/jn. 2000.83.3.1]. [PMID: 10712].","journal-title":"J Neurophysiol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","volume":"61","author":"Strupp M.","year":"2003","unstructured":"Strupp M, Sch\u00fcler O, Krafczyk S, Jahn K, Schautzer F, B\u00fcttner U, Brandt T. Neurology, Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.,, 2003, 61,, 165-170,[http:\/\/dx.doi.org\/10.1212\/01.WNL.0000078893. 41040.]. [PMID: 12874].","journal-title":"Neurology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1093\/brain\/awm172","volume":"130","author":"Kalla R.","year":"2007","unstructured":"Kalla R, Glasauer S, B\u00fcttner U, Brandt T, Strupp M. Brain, 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.,, 2007, 130,, 2441-2451,[http:\/\/dx.doi.org\/10.1093\/brain\/awm]. [PMID: 17664].","journal-title":"Brain"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/WNO.0b013e3182258086","volume":"31","author":"Kalla R.","year":"2011","unstructured":"Kalla R, Spiegel R, Claassen J, Bardins S, Hahn A, Schneider E, Rettinger N, Glasauer S, Brandt T, Strupp M. J Neuroophthalmol, Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.,, 2011, 31,, 320-325,[http:\/\/dx.doi.org\/10.1097\/ WNO.0b013e31822580]. [PMID: 217345].","journal-title":"J Neuroophthalmol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1007\/s00415-013-6911-5","volume":"260","author":"Claassen J.","year":"2013","unstructured":"Claassen J, Feil K, Bardins S, Teufel J, Spiegel R, Kalla R, Schneider E, Jahn K, Schniepp R, Strupp M. J Neurol, Dalfampridine in patients with downbeat nystagmus--an observational study.,, 2013, 260,, 1992-1996,[http:\/\/dx.doi.org\/10.1007\/s00415-013-6911-]. [PMID: 23589].","journal-title":"J Neurol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/CPJ.0000000000000321","volume":"7","author":"Strupp M.","year":"2017","unstructured":"Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K. Neurol Clin Pract, Aminopyridines for the treatment of neurologic disorders.,, 2017, 7,, 65-76,[http:\/\/dx.doi.org\/10.1212\/ CPJ.0000000000000]. [PMID: 2824350].","journal-title":"Neurol Clin Pract"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","volume":"87","author":"Ophoff R.A.","year":"1996","unstructured":"Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR. Cell, Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.,, 1996, 87,, 543-552,[http:\/\/ dx.doi.org\/10.1016\/S0092-8674(00)81373-]. [PMID: 8898].","journal-title":"Cell"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.WNL.0000101675.61074.50","volume":"62","author":"Jen J.","year":"2004","unstructured":"Jen J, Kim GW, Baloh RW. Neurology, Clinical spectrum of episodic ataxia type 2.,, 2004, 62,, 17-22,[http:\/\/dx.doi. org\/10.1212\/01.WNL.0000101675.61074.]. [PMID: 147186].","journal-title":"Neurology"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1196\/annals.1444.016","volume":"1142","author":"Jen J.C.","year":"2008","unstructured":"Jen JC. Ann N Y Acad Sci, Hereditary episodic ataxias.,, 2008, 1142,, 250-253,[http:\/\/dx.doi.org\/10.1196\/annals.1444.0]. [PMID: 18990].","journal-title":"Ann N Y Acad Sci"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1749-6632.2008.03723.x","volume":"1164","author":"Jen J.C.","year":"2009","unstructured":"Jen JC, Baloh RW. Ann N Y Acad Sci, Familial episodic ataxia: a model for migrainous vertigo.,, 2009, 1164,, 252-256,[http:\/\/ dx.doi.org\/10.1111\/j.1749-6632.2008.03723.x]. [PMID: 1964590].","journal-title":"Ann N Y Acad Sci"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000343814","volume":"69","author":"Neugebauer H.","year":"2013","unstructured":"Neugebauer H, Adrion C, Glaser M, Strupp M. Eur Neurol, Long-term changes of central ocular motor signs in patients with vestibular migraine.,, 2013, 69,, 102-107,[http:\/\/dx.doi.org\/ 10.1159\/0003438]. [PMID: 231829].","journal-title":"Eur Neurol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.28.12.1259","volume":"28","author":"Griggs R.C.","year":"1978","unstructured":"Griggs RC, Moxley RT, Lafrance RA, McQuillen J. Neurology, Hereditary paroxysmal ataxia: response to acetazolamide.,, 1978, 28,, 1259-1264,[http:\/\/dx.doi.org\/10.1212\/WNL. 28.12.1]. [PMID: 366].","journal-title":"Neurology"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","volume":"62","author":"Strupp M.","year":"2004","unstructured":"Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Neurology, Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.,, 2004, 62,, 1623-1625,[http:\/\/dx.doi.org\/10.1212\/01.WNL.0000125691.74109.]. [PMID: 151366].","journal-title":"Neurology"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","volume":"77","author":"Strupp M.","year":"2011","unstructured":"Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K. Neurology, A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.,, 2011, 77,, 269-275,[http:\/\/ dx.doi.org\/10.1212\/WNL.0b013e318225ab0]. [PMID: 21734].","journal-title":"Neurology"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00415-012-6764-3","volume":"260","author":"Claassen J.","year":"2013","unstructured":"Claassen J, Teufel J, Kalla R, Spiegel R, Strupp M. J Neurol, Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.,, 2013, 260,, 668-669,[http:\/\/dx. doi.org\/10.1007\/s00415-012-6764-]. [PMID: 231839].","journal-title":"J Neurol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1523\/JNEUROSCI.0905-11.2011","volume":"31","author":"Hourez R.","year":"2011","unstructured":"Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d\u2019Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN. J Neurosci, Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.,, 2011, 31,, 11795-11807,[http:\/\/dx.doi.org\/ 10.1523\/JNEUROSCI.0905-11.20]. [PMID: 218495].","journal-title":"J Neurosci"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"11795","DOI":"10.1523\/JNEUROSCI.0905-11.2011","volume":"31","author":"Hourez R.","year":"2011","unstructured":"Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d\u2019Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN. J Neurosci, Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.,, 2011, 31,, 11795-11807,[http:\/\/dx.doi.org\/ 10.1523\/JNEUROSCI.0905-11.20]. [PMID: 218495].","journal-title":"J Neurosci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1007\/s00415-011-5987-z","volume":"258","author":"Schniepp R.","year":"2011","unstructured":"Schniepp R, Wuehr M, Ackl N, Danek A, Brandt T, Strupp M, Jahn K. J Neurol, 4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.,, 2011, 258,, 1708-1711,[http:\/\/dx.doi.org\/10.1007\/s00415-011-5987-z]. [PMID: 21431].","journal-title":"J Neurol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00415-012-6595-2","volume":"259","author":"Schniepp R.","year":"2012","unstructured":"Schniepp R, Wuehr M, Neuhaeusser M, Benecke AK, Adrion C, Brandt T, Strupp M, Jahn K. J Neurol, 4-aminopyridine and cerebellar gait: a retrospective case series.,, 2012, 259,, 2491-2493,[http:\/\/dx.doi.org\/10.1007\/s00415-012-6595-]. [PMID: 227609].","journal-title":"J Neurol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00415-013-7029-5","volume":"260","author":"Giordano I.","year":"2013","unstructured":"Giordano I, Bogdanow M, Jacobi H, Jahn K, Minnerop M, Schoels L, Synofzik M, Teufel J, Klockgether T. J Neurol, Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.,, 2013, 260,, 2175-2176,[http:\/\/dx.doi.org\/10.1007\/s00415-013-7029-]. [PMID: 23824].","journal-title":"J Neurol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"Strupp M.","year":"2013","unstructured":"Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg BP, Klopstock T, Feil K. J Neurol, Effects of acetyl-DL-leucine in patients with cerebellar ataxia: a case series.,, 2013, 260,, 2556-2561,[http:\/\/dx.doi.org\/10.1007\/s00415-013-7016-x]. [PMID: 238356].","journal-title":"J Neurol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.0000000000002041","volume":"85","author":"Bremova T.","year":"2015","unstructured":"Bremova T, Malinov\u00e1 V, Amraoui Y, Mengel E, Reinke J, Koln\u00edkov\u00e1 M, Strupp M. Neurology, Acetyl-dl-leucine in Niemann-Pick type C: A case series.,, 2015, 85,, 1368-1375,[http:\/\/dx. doi.org\/10.1212\/WNL.00000000000020]. [PMID: 264005].","journal-title":"Neurology"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40673-016-0046-2","volume":"3","author":"Schniepp R.","year":"2016","unstructured":"Schniepp R, Strupp M, Wuehr M, Jahn K, Dieterich M, Brandt T, Feil K. Cerebellum Ataxias, Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series.,, 2016, 3,, 8-,[http:\/\/dx.doi.org\/10.1186\/s40673-016-0046-]. [PMID: 270736].","journal-title":"Cerebellum Ataxias"},{"key":"ref=49","author":"Highstein S.M.","unstructured":"Highstein SM, Holstein GR, , ,The anatomy of the vestibular nuclei. Prog. Brain Res., 2006, 151, 157-203. [http:\/\/dx.doi.org\/10. 1016\/S0079-6123(05)51006-9] [PMID: 16221589], , , , ,-"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.0953-816x.2000.01447.x","volume":"13","author":"Vibert N.","year":"2001","unstructured":"Vibert N, Vidal PP. Eur J Neurosci, \n                        In vitro effects of acetyl-DL-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig.,, 2001, 13,, 735-748,[http:\/\/ dx.doi.org\/10.1046\/j.0953-816x.2000.01447.x]. [PMID: 1120780].","journal-title":"Eur J Neurosci"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.biophys.37.032807.125859","volume":"37","author":"Suh B.C.","year":"2008","unstructured":"Suh BC, Hille B. Annu Rev Biophys, PIP2 is a necessary cofactor for ion channel function: how and why?,, 2008, 37,, 175-195,[http:\/\/dx.doi.org\/10.1146\/annurev.biophys.37.032807.1258]. [PMID: 185730].","journal-title":"Annu Rev Biophys"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fncir.2013.00133","volume":"7","author":"Witter L.","year":"2013","unstructured":"Witter L, Canto CB, Hoogland TM, de Gruijl JR, De Zeeuw CI. Front Neural Circuits, Strength and timing of motor responses mediated by rebound firing in the cerebellar nuclei after Purkinje cell activation.,, 2013, 7,, 133-,[http:\/\/dx.doi.org\/10.3389\/ fncir.2013.00]. [PMID: 239708].","journal-title":"Front Neural Circuits"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"e0120891","DOI":"10.1371\/journal.pone.0120891","volume":"10","author":"G\u00fcnther L.","year":"2015","unstructured":"G\u00fcnther L, Beck R, Xiong G, Potschka H, Jahn K, Bartenstein P, Brandt T, Dutia M, Dieterich M, Strupp M, la Foug\u00e8re C, Zwergal A. PLoS One, N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus.,, 2015, 10,, e0120891-,[http:\/\/ dx.doi.org\/10.1371\/journal.pone.01208]. [PMID: 258036].","journal-title":"PLoS One"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/jnc.12044","volume":"123","author":"Hull J.","year":"2012","unstructured":"Hull J, Hindy ME, Kehoe PG, Chalmers K, Love S, Conway ME. J Neurochem, Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation.,, 2012, 123,, 997-1009,[http:\/\/dx.doi.org\/10.1111\/ jnc.120]. [PMID: 23043].","journal-title":"J Neurochem"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cne.20200","volume":"477","author":"Sweatt A.J.","year":"2004","unstructured":"Sweatt AJ, Garcia-Espinosa MA, Wallin R, Hutson SM. J Comp Neurol, Branched-chain amino acids and neurotransmitter metabolism: expression of cytosolic branched-chain aminotransferase (BCATc) in the cerebellum and hippocampus.,, 2004, 477,, 360-370,[http:\/\/dx.doi.org\/10.1002\/cne.20]. [PMID: 153298].","journal-title":"J Comp Neurol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1113\/jphysiol.2002.024281","volume":"545","author":"Johnston A.R.","year":"2002","unstructured":"Johnston AR, Seckl JR, Dutia MB. J Physiol, Role of the flocculus in mediating vestibular nucleus neuron plasticity during vestibular compensation in the rat.,, 2002, 545,, 903-911,[http:\/\/dx.doi.org\/10.1113\/jphysiol.2002.024]. [PMID: 124828].","journal-title":"J Physiol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00405-003-0644-5","volume":"261","author":"Murai N.","year":"2004","unstructured":"Murai N, Tsuji J, Ito J, Mishina M, Hirano T. Eur Arch Otorhinolaryngol, Vestibular compensation in glutamate receptor delta-2 subunit knockout mice: dynamic property of vestibulo-ocular reflex.,, 2004, 261,, 82-86,[http:\/\/dx.doi.org\/10.1007\/s00405-003-0644-].","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12883-016-0786-x","volume":"17","author":"Feil K.","year":"2017","unstructured":"Feil K, Adrion C, Teufel J, B\u00f6sch S, Claassen J, Giordano I, Hengel H, Jacobi H, Klockgether T, Klopstock T, Nachbauer W, Sch\u00f6ls L, Stendel C, Uslar E, van de Warrenburg B, Berger I, Naumann I, Bayer O, M\u00fcller HH, Mansmann U, Strupp M. BMC Neurol, Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.,, 2017, 17,, 7-,[http:\/\/dx.doi.org\/10.1186\/ s12883-016-0786-x]. [PMID: 280689].","journal-title":"BMC Neurol"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T17:38:17Z","timestamp":1569260297000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165120\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x16666180905093535","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}